Compare EVAX & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVAX | TVRD |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | Denmark | United States |
| Employees | N/A | 12 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.9M | 29.1M |
| IPO Year | 2020 | N/A |
| Metric | EVAX | TVRD |
|---|---|---|
| Price | $4.35 | $3.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 7 |
| Target Price | $11.67 | ★ $29.50 |
| AVG Volume (30 Days) | 30.2K | ★ 46.6K |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $328.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $2.75 |
| 52 Week High | $12.15 | $43.65 |
| Indicator | EVAX | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 44.84 |
| Support Level | $2.64 | $2.75 |
| Resistance Level | $4.62 | $3.50 |
| Average True Range (ATR) | 0.32 | 0.23 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 30.71 | 34.33 |
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.